Clinical Trial Update: Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating two dosing regimens of olokizumab versus placebo in rheumatoid arthritis patients on TNF inhibitor therapy; study completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Olokizumab (olokizumab)

Snippet

Sponsor: R-Pharm International, LLC | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2021-07-21